摘要
目的观察FOLFOX4方案联合肝动脉化疗栓塞术(TACE)治疗不能手术的结直肠癌肝转移患者的疗效及不良反应。方法收集已经临床明确诊断不能手术的结直肠癌肝转移患者42例,依据治疗方案分为FOLFOX4方案组(化疗组,n=20)及FOLFOX4+TACE组(联合组,n=22):联合组接受FOLFOX4方案化疗3周期后行TACE治疗1次,每6周评价疗效。以RECIST1.1标准评价近期疗效,以NCI CTC3.0评价毒性反应。结果 42例患者均可评价近期疗效和毒副反应。化疗组与联合组的客观有效率(RR)分别为25.0%(5/20)和40.9%(9/22),疾病控制率(DCR)分别为60.0%(12/20)和77.3%(17/22)。两组间RR和DCR的差异无统计学意义(P>0.05)。联合组的腹痛、肝功能损害、发热的发生率高于化疗组,差异有统计学意义(P<0.05)。结论 FOLFOX4方案联合TACE治疗不能手术切除结直肠癌肝转移具有一定的疗效,毒副反应可以耐受,安全性好,值得临床进一步研究。
Objective To investigate the efficacy and side effects of FOLFOX4 regimen combined with transcatheter arte-rial chemoembolization( TACE) for the treatment of patients with hepatic metastases of inoperable colorectal cancer. Methods 42 patients with hepatic metastases of inoperable colorectal cancer were included. 20 of them received FOLFOX4 chemotherapy ( Chemo Group) . 22 of them received FOLFOX4 regimen combined with TACE ( Combined Group):TACE was performed once af-ter three cycles of FOLFOX4 chemotherapy. The efficacy were evaluated every 6 weeks. The short-time effect was evaluated by RECIST standard. The side effects were evaluated according to NCI CTC3. 0. Results RR was 25. 0% in Chemo Group and 40. 9% in Combined Group. DCR was 60. 0% in Chemo Group and 77. 3% in Combined Group. There was no significant differ-ence between the two groups(P>0. 05). The side-effects including abdominal pain,hepatic dysfunction,and fever were much com-mon in Combined Group compared to Chemo Group ( P<0. 05 ) . Conclusion FOLFOX4 regimen combined with TACE for the treatment of patients with hepatic metastases of inoperable colorectal cancer is effective and safe,which is worth to be further stud-ied.
出处
《四川医学》
CAS
2014年第11期1449-1452,共4页
Sichuan Medical Journal
